Transcat (NASDAQ:TRNS) Announces Quarterly Earnings Results, Beats Estimates By $0.19 EPS

Transcat (NASDAQ:TRNS) released its quarterly earnings data on Tuesday. The scientific and technical instruments company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.45 by $0.19, FiscalAI reports. Transcat had a net margin of 0.99% and a return on equity of 5.56%. The business had revenue of $97.09 million for the quarter, compared to analyst estimates of $92.46 million.

Here are the key takeaways from Transcat’s conference call:

• Strong second-quarter growth: Revenue increased 18% to $97.1 million, while adjusted EBITDA rose 23% and adjusted EPS grew 46% to $0.64. Service revenue grew 23%, including 16% organic growth, marking the 70th consecutive quarter of year-over-year service growth.
• Service profitability improved substantially: Service gross margin expanded 220 basis points to 34.4%, helped by operating leverage, pricing, business-mix improvements, and operational-excellence initiatives. Management expects at least 100 basis points of year-over-year service gross-margin expansion in the second half.
• Full-year service outlook was raised: Transcat increased its fiscal 2027 service organic revenue-growth forecast from high single digits to low double digits, citing broad-based demand, market-share gains, improved sales execution, and better visibility into large customer wins.
• Acquisition and rental strategies remain key growth drivers: The Southeastern Biomedical Associates acquisition expands Transcat’s reach in biomedical calibration and hospital networks, while rentals are expected to grow at a low-double-digit rate over time. Distribution margins declined year over year because of lower-margin used-equipment sales, but management expects distribution-margin improvement in the second half.
• Financial capacity supports continued expansion: Operating free cash flow rose 46% to $10.9 million in the first half, while quarter-end debt was $116.9 million, with $33.1 million available under the revolving credit facility and leverage of 2.18 times.

Transcat Stock Performance

TRNS stock traded up $1.60 on Tuesday, reaching $89.52. The company’s stock had a trading volume of 330,569 shares, compared to its average volume of 145,248. Transcat has a 52 week low of $50.23 and a 52 week high of $100.00. The firm has a fifty day moving average of $86.05 and a two-hundred day moving average of $81.71. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.49 and a quick ratio of 2.11. The company has a market capitalization of $840.59 million, a P/E ratio of 241.95 and a beta of 0.66.

Wall Street Analyst Weigh In

TRNS has been the topic of a number of recent analyst reports. CJS Securities started coverage on shares of Transcat in a research note on Tuesday, October 27th. They set an “outperform” rating and a $115.00 price target on the stock. Weiss Ratings reiterated a “sell (d+)” rating on shares of Transcat in a research note on Tuesday, August 25th. Finally, Northland Securities raised shares of Transcat from a “market perform” rating to an “outperform” rating and set a $95.00 price target for the company in a research report on Wednesday, October 21st. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Transcat has a consensus rating of “Hold” and an average price target of $105.00.

Insider Buying and Selling at Transcat

In related news, Director Christopher Gillette sold 504 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $94.23, for a total value of $47,491.92. Following the completion of the sale, the director owned 200 shares of the company’s stock, valued at approximately $18,846. The trade was a 71.59% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Craig D. Cairns bought 1,050 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were bought at an average price of $93.97 per share, for a total transaction of $98,668.50. Following the completion of the acquisition, the director owned 1,480 shares of the company’s stock, valued at approximately $139,075.60. This represents a 244.19% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 1.80% of the company’s stock.

Transcat Company Profile

Transcat, Inc (NASDAQ: TRNS) provides calibration, compliance, and measurement services for organizations that rely on accurate test and measurement equipment. The company supports customers in regulated industries, including life sciences, aerospace and defense, energy, manufacturing, and other industrial markets.

Its service offerings include laboratory and onsite calibration, repair, validation, and asset-management services. Transcat calibrates a broad range of equipment used to measure temperature, pressure, electrical and electronic properties, radio frequency signals, dimensional characteristics, and other technical parameters.